logo

Syros Pharmaceuticals (SYRS)



Trade SYRS now with
  Date
  Headline
9/15/2022 4:05:06 PM Syros And Tyme Technologies Announce Stockholder Approval Of Merger
8/9/2022 7:46:46 AM Syros Pharma Q2 Net Loss $34.5 Mln Or $0.54/shr Vs Net Loss $22.5 Mln Or $0.36/shr Prior Year
7/5/2022 8:52:49 AM Syros Pharma To Buy Tyme Technologies
5/16/2022 7:53:32 AM Syros Pharma Q1 Net Loss $25.1 Mln Or $0.40/Shr Vs Loss Of $14.2 Mln Or $0.23/Shr Last Year
2/28/2022 7:41:39 AM Acerus Agrees To Acquire Serenity LLC And The Global Rights To Noctiva
11/5/2021 7:46:43 AM Syros Pharma Q3 Net Loss $26.0 Mln Or $0.41/shr Vs. Net Loss Of $19.5 Mln Or $0.43/shr Prior Year
10/12/2021 8:08:54 AM Syros Pharma Appoints Jason Haas As CFO
9/29/2021 8:08:41 AM Syros:First Patient In Dose Confirmation Study Of SY-2101,Oral Form Of Arsenic Trioxide, In Acute Promyelocytic Leukemia
9/9/2021 8:12:33 AM Syros:First Patient Dosed In Trial Of Tamibarotene In Combination With Venetoclax & Azacitidine In Diagnosed Unfit AML
8/5/2021 7:51:47 AM Syros Q2 Net Loss $22.5 Mln Or $0.36/Shr Vs Loss Of $17.2 Mln Or $0.38/Shr Last Year
5/2/2019 8:31:49 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) FY19 Estimate To -1.99 From -2.29
5/2/2019 8:31:32 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) Q4 19 Estimate To -0.46 From -0.47
5/2/2019 8:31:18 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) Q3 19 Estimate To -0.60 From -0.61